<b>Conclusion:</b> Collectively, these findings demonstrate that baclofen exerts anti-glioma effects through GABAB receptor-mediated inhibition of the MEK/ERK/CREB signaling axis and modulation of the EMT-like pathway, thereby highlighting the potential of baclofen as a therapeutic agent for glioma. This evidence concerns the gene CREB1 and central nervous system cancer.